Felissa R. Lashley, RN, PhD, ACRN, FAAN, FACMG
The emergence and re-emergence of infectious diseases involves many interrelated factors. Global interconnectedness continues to increase with international travel and trade; economic, political, and cultural interactions; and human-to-human and animal-to-human interactions. These interactions include the accidental and deliberate sharing of microbial agents and antimicrobial resistance and allow the emergence of new and unrecognized microbial disease agents. As the 21st century begins, already new agents have been identified, and new outbreaks have occurred. Solutions to limiting the spread of emerging infectious diseases will require cooperative efforts among many disciplines and entities worldwide. This article defines emerging infectious diseases, summarizes historical background, and discusses factors that contribute to emergence. Seven agents that have made a significant appearance, particularly in the 21st century, are reviewed, including: Ebola and Marburg hemorrhagic fevers, human monkeypox, bovine spongiform encephalopathy, severe acute respiratory syndrome (SARS), West Nile virus, and avian influenza. The article provides for each agent a brief historical background, case descriptions, and health care implications.
Citation: Lashley, F., (January 31, 2006). "Emerging Infectious Diseases at the Beginning of the 21st Century". Online Journal of Issues in Nursing. Vol. 11 No. 1, Manuscript 1.
Key words: avian influenza, bovine spongiform encephalopathy, Ebola virus, emerging infectious diseases, hemorrhagic fevers, infectious diseases, Marburg virus, monkeypox, prion diseases, SARS, viral infections, West Nile virus
Worldwide, infectious diseases place a considerable burden on individuals and health care.
Worldwide, infectious diseases place a considerable burden on individuals and health care. In general, infectious diseases exact a greater toll from infants, young children and the elderly, and disproportionately affect disadvantaged populations in developed countries. With the coming of the golden age of antibiotics and other antimicrobial agents, many health care practitioners anticipated that infectious diseases could be conquered or controlled. This view proved overly optimistic. Microbes and their hosts exist in a relationship influenced by their environment. This relationship, precariously balanced and continuously evolving, contributes to the emergent nature of threats from infectious diseases.
This article defines emerging infectious diseases (EIDs), summarizes historical background, and discusses factors that contribute to emergence. Seven agents that have made a significant appearance, particularly in the 21st century, are reviewed, including: Ebola and Marburg hemorrhagic fevers, human monkeypox, bovine spongiform encephalopathy (BSE), severe acute respiratory syndrome (SARS), West Nile virus, and avian influenza.
Focused attention to EIDs began in the late 1960s and early 1970s. EIDs received greater interest with the emergence of HIV/AIDS in the early 1980s, and this attention culminated in a report on emerging and re-emerging infections in 1992 by the Institute of Medicine (IOM) (Smolinski, Hamburg & Lederberg, 2003). In 1995, a dedicated journal, Emerging Infectious Diseases, was introduced by the Centers for Disease Control and Prevention (CDC). The definition of emerging infectious diseases varies somewhat and depends on who does the defining, the time the definition is offered, and whether the definition should be restrictive or inclusive. The following description (Lashley, 2003, 2004; Lashley & Durham, 2002; Lederberg, Shope & Oaks, 1992) incorporates an inclusive definition of EIDs, and includes examples where relevant:
- Newly identified diseases caused by a previously known microorganism. An example is group A Streptococcus infection resulting in toxic shock syndrome.
- Newly identified diseases caused by a previously unknown or unrecognized microorganism. An example is acquired immunodeficiency syndrome (AIDS), now known to result from the human immunodeficiency virus (HIV).
- Known diseases newly realized to be caused by a previously known microorganism. An example is peptic ulcer found to result from Helicobacter pylori infection.
- Diseases and microorganisms found in new geographic areas. An example is West Nile virus in the Western hemisphere, causing encephalitis.
- Microorganisms found to be resistant to antimicrobial agents. Examples of recent concern include multidrug-resistant tuberculosis (MDR-TB), vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
- Microorganisms of animals that have extended their host range to newly infect humans. An example is avian influenza.
- Newly identified reservoirs or vectors for microorganisms. An example is the 1966 identification of cattle as reservoir hosts for Trypanosoma brucei rhodesiense, the cause of Rhodesian sleeping sickness.
- Microbial evolution resulting in a change of virulence or other characteristics. An example is Escherichia coli, with most strains being relatively benign in humans, but O157:H7 having the ability to cause severe illness and hemolytic uremic syndrome.
- Known diseases that have markedly increased in incidence. Examples are diphtheria and pertussis, especially in nations with deteriorating public health infrastructures.
- Organisms that have been deliberately altered to cause intentional harm such as weaponized Bacillus anthracis that was used to contaminate some mail in the United States in 2001.
...since the early 1990s, there has been an increasing number of new infectious agents and species identified, and outbreaks or resurgence of previously known illnesses have been detected.
In some cases, identification of the cause of EIDs has awaited the development of appropriate diagnostic technology. Some cancers and chronic diseases are due to microbial infection, and it is anticipated that even more will ultimately be shown to have a microbial contribution.
Emerging, or re-emerging, infectious agents or diseases began to be identified in the late 1960s and early 1970s, but it was not until the early 1990s that their potential impact began to attract significant attention. The most recent 2003 report from the IOM entitled "Microbial Threats to Health: Emergence, Detection, and Response" (Smolinski, Hamburg, & Lederberg, 2003) indicates that since the early 1990s, there has been an increasing number of new infectious agents and species identified, and outbreaks or resurgence of previously known illnesses have been detected. Beginning in 1992, with the emergence of Sin Nombre virus (cause of hantavirus pulmonary syndrome), the list of new pathogens and diseases continues into the 21st century with an outbreak of SARS due to a newly identified coronavirus; an outbreak of human monkeypox in the Western hemisphere; human cases of avian influenza in Asia; the identification of bovine spongiform encephalopathy-infected cattle in the United States; outbreaks of Marburg hemorrhagic fever in Angola and Ebola hemorrhagic fever in the Democratic Republic of the Congo; and the establishment of West Nile virus as endemic in North America. Selected new pathogens and the resulting infectious diseases identified since 1992 are listed in the Table below (Lashley, 2004). One should also keep in mind that emerging infectious diseases appear alongside the palette of the more common infectious diseases.
Table. Selected new pathogenic agents/ infectious diseases identified since 1992§
||Human granulocytic anaplasmosis
|Australian bat lyssavirus
||Cat scratch disease
||Enteritis, disseminated infection
- Sin Nombre virus
- Whitewater Arroyo virus
|Hantavirus pulmonary syndrome
||Encephalitis, respiratory disease
|Hepatitis G virus
||Acute respiratory infections, pneumonia
||Severe acute respiratory syndrome
|Vibrio parahaemolyticus serotype 03K6
|§Agents identified prior to this time that were associated with large outbreaks in the specified period, such as West Nile, Ebola or Marburg viruses, are not included. This table is not all inclusive.
Contributing Factors to Emergence of Infectious Diseases
The 2003 IOM report (Smolinski, Hamburg & Lederberg, 2003) divided factors of emergence into 13 basic categories. These categories are listed below, with an example of each in parentheses. Further discussion on contributing factors may be found in "Emerging Infectious Diseases: Vulnerabilities, Contributing Factors, and Approaches" (Lashley, 2004).
- Microbial adaptation and change (e.g., the O157:H7 strain of E. coli, which is more virulent).
- Human susceptibility to infection (e.g., persons who are homozygous for methionine on codon 129 of the prion protein gene [PRNP] are more susceptible to development of Creutzfeldt-Jakob disease).
- Climate and weather (e.g., heavy rains can result in increased breeding sites for mosquito vectors and increases in mosquito-borne infectious diseases).
- Changing ecosystems (e.g., dam building has resulted in changing vector ecology and the emergence of Rift Valley hemorrhagic fever in Egypt).
- Human demographics and behavior (e.g., body piercing and potential hepatitis C infection).
- Economic development and land use (e.g., clearing forests in Venezuela has resulted in an increased cane mouse population, the probable reservoir host of the Guanarito virus and an outbreak of Venezuelan hemorrhagic fever).
- International travel and commerce (e.g., importation of Guatemalan raspberries and outbreaks of cyclosporiasis in the United States).
- Technology and industry (e.g., use of mass treatment with fluoroquinolones to treat E. coli infections in chickens, resulting in antimicrobial resistance in humans to other organisms).
- Breakdown of public health measures (e.g., breakdown in vector control, leading to increased abundance and distribution of Aedes aegyptii, the mosquito vector of dengue, and hence a spread of dengue hemorrhagic fever to the Americas).
- Poverty and social inequality (e.g., poverty can result in the eating of animals who have died from disease, resulting in human infections such as in the case of gastrointestinal anthrax in humans).
- War and famine (e.g., civil unrest and natural disasters). Any mass disruption and violence can result in disruption of public health services, especially preventive services, such as immunizations and vector controls.
- Lack of political will (e.g., the lack of reporting of global infectious diseases of interest for political and economic reasons, such as with SARS in China).
- Intent to harm (e.g., the intentional distribution of Bacillus anthracis, the etiologic agent of anthrax in the United States in 2001).
Many of these contributing factors are interrelated. For example, war creates crowded conditions leading to contaminated drinking water, unsanitary facilities, disruption of basic health services, and easier spread of infectious agents. War can also result in lack of food for those who are politically disenfranchised and in famine. Famine results in malnutrition, which then alters human susceptibility to infection. Victims of war are also prey for violence and sexual predators resulting in the spread of sexually-transmitted diseases, such as HIV. The interrelated nature of these contributing factors is also evident in the following section in the discussion of seven agents that have made a significant appearance as EIDs.
Selected Specific Emerging Infectious Diseases
Among the newer emerging infectious agents and diseases, many have already had great impact...
Among the newer emerging infectious agents and diseases, many have already had great impact, while others show potential for impact in the near future. Agents that have made a significant appearance, particularly in the 21st century, are considered in more depth below. These agents include: Ebola and Marburg hemorrhagic fevers, human monkypox, BSE, SARS, West Nile virus, and avian influenza.
Hemorrhagic Fevers: The Ebola and Marburg Viruses
The Ebola and Marburg viruses are the only known members of the filovirus family. They can cause severe hemorrhagic fever with high fatality rates. There is no specific treatment. Ebola virus is better known to the public as a result of discussion in the popular media, such as in the book by Richard Preston, "The Hot Zone: A Terrifying True Story," (1994), and the movie "Outbreak," starring Dustin Hoffman (Warner Brothers Pictures, 1995). The natural animal reservoir of both is still unknown.
Ebola Hemorrhagic Fever. Ebola virus infection was first recognized during a human outbreak in 1976 with almost simultaneous outbreaks in both the Sudan and Zaire (now the Democratic Republic of the Congo). It was named after a river in the Democratic Republic of the Congo (Peters & LeDuc, 1999) The Ebola virus is now known to have four subtypes: Zaire, Sudan, Reston, and Ivory Coast (Pourrut et al., 2005). After an outbreak in 1979 in the Sudan, Ebola appeared relatively quiescent until it appeared among macaque monkeys imported from the Philippines and housed at a primate facility in Reston, Virginia (Peters & LeDuc). In late 1994, a single case in a researcher who performed a necropsy on an ill chimpanzee led to the identification of a new subtype, Ebola-Ivory Coast (Arthur, 2002).
...human outbreaks [of Ebola virus infection] tended to follow those observed in animals.
In Gabon, Africa, outbreaks of Ebola virus infection occurred from 1994 to 1997 (Georges et al., 1999). Another appearance was in 2000-2001 with an Ebola outbreak in Uganda that resulted in 425 cases with 224 deaths by January 2001 (CDC, 2001). In this outbreak, events and conditions associated with acquired disease were: funeral attendance for those who died with Ebola hemorrhagic fever, intrafamilial contact, and nosocomial infections. Schools were closed and a ban against funerals was enacted (World Health Organization [WHO], 2001).
In November, 2001, an Ebola outbreak again occurred in Gabon. and in the Democratic Republic of the Congo, and multiple outbreaks occurred in 2000-2004 in Gabon, the Congo, Sudan, and Uganda. Outbreaks continue in the Congo in 2005. At the same time, it was noted that Ebola outbreaks occurred in large mammals, mainly chimpanzees, duikers (a type of antelope), and gorillas, and that human outbreaks tended to follow those observed in animals. Airborne transmission of the Ebola Zaire strain to monkeys by aerosol has been demonstrated (Johnson, Jaax, White, & Jahrling, 1995) but is not known to occur from human-to-human. To date, no animal reservoir for Ebola virus has been identified (Pourrut et al., 2005).
Marburg Hemorrhagic Fever. Marburg virus infection was identified in 1967, when laboratory workers in a pharmaceutical company in Marburg, Germany who were processing tissue from imported African green monkeys began to fall ill. The workers were admitted to the hospital with severe illness. The virus isolated was unrelated to any other known at that time. Other cases occurred at virtually the same time in Frankfurt, Germany and in what was then Belgrade, Yugoslavia (now Serbia) (Peters & LeDuc, 1999). It was determined that the monkeys in all three sites were from the same imported batch from Uganda. The full investigation ultimately led to the recognition of a new family of viruses, the Filoviridiae, of which Marburg virus was the first to be identified (Feldmann & Kiley, 2000).
Transmission of [Ebola and Marburg viruses] occurs by direct contact with infected body fluids from animals and humans...
Marburg virus was not recognized again until 1975 when three cases were reported from Johannesburg, South Africa. The index case (initial patient) was a young Australian man who had been on vacation doing a walkabout in what was then Rhodesia (now Zimbabwe) with a female companion. He died, but his companion, and the nurse caring for both of them, recovered (WHO, 2005a). In 1980, Marburg virus infection was next recognized when an index patient became ill in western Kenya, followed by secondary illness of the physician who tried to resuscitate him (Smith et al., 1982). From 1980 until 1998, outbreaks of Marburg virus infection were relatively few and involved a single or a few primary cases. In 1982, another single case was identified in South Africa. In late 1998, an outbreak of Marburg virus hemorrhagic fever occurred in Durba, in the Democratic Republic of the Congo. Many affected were illegal gold miners in abandoned mines. The remote location and local warfare prevented arrival of experts from the CDC and WHO for months. In October 2004, a very large outbreak began in Angola and was declared over in November 2005. As of November 2005, 374 cases of Marburg hemorrhagic fever were reported, and 329 were fatal (WHO, 2005b; 2005c).
Marburg hemorrhagic fever has affected many fewer persons than Ebola virus. Thus, the recent large outbreak that was declared over in November 2005 is of particular interest, especially since before this outbreak, cases in children were rare, and in this outbreak, children account for a high proportion of those affected. Transmission of these viruses occurs by direct contact with infected body fluids from animals and humans, such as blood, saliva, vomitus, respiratory droplets, urine and stool, and contact with virus-contaminated objects (e.g., needles, syringes). Persons who prepare, cook, and eat contaminated animals may become infected. Person-to-person transmission occurs, as does infection from direct inoculation. Transmission via semen may occur weeks after recovery (CDC, 2005a; WHO, 2001).
It is extremely important to use proper barrier nursing techniques to prevent secondary cases of Ebola and Marburg virus hemorrhagic fevers to caretakers and families, including use of standard, contact, and airborne isolation precautions. Updated information for infection control for patients with viral hemorrhagic fevers in U.S. hospitals may be found on the CDC website (2005a). There is also concern about use of the filoviruses as bioterror agents, especially if the viruses could be modified to efficiently spread via aerosol from person-to-person.
[Monkeypox] is considered to be the most important orthopoxvirus infections in humans outside of smallpox.
Monkeypox results from an orthopoxvirus which has some similarities to the smallpox virus, variola. It is considered to be the most important orthopoxvirus infection in humans outside of smallpox, which has been eradicated in its natural state. Monkeypox was first identified in laboratory monkeys in 1958, and the first human case was reported in 1970 in a child in the Democratic Republic of the Congo. It is now considered endemic in parts of central and western Africa (DiGiulio & Eckburg, 2004a, 2004b).
In May of 2003, the first cases in the United States of what was later found to be monkeypox were reported among members of a family in Wisconsin (a woman and man in their early 30s and their young daughter). The family had bought two prairie dogs as pets 11 days before the mother developed fever, headache, sore throat, dyspnea, and malaise along with a small papule. The mother subsequently developed a more severe rash with more than 200 lesions. The outbreak was initially misdiagnosed as a possible staphylococcal infection (CDC, 2003a; Sejvar et al., 2004). The daughter presented with more severe illness that included rash, lymphadenopathy, malaise, enlarged tonsils, and fever. She eventually developed encephalitis, became unresponsive, and required intensive care. Initially it was believed that she might have contracted a viral encephalitis (such as from varicella or herpes simplex virus), but the diagnosis of monkeypox was confirmed. A fourth case was diagnosed in the distributor of exotic animals who had sold the two prairie dogs to the family first affected, thus establishing an epidemiological link between them (Reed et al., 2004).
Epidemiological investigation revealed that those two prairie dogs and others were co-housed with an infected Gambian giant rat from Ghana and other exotic rodent species. Additional infected prairie dogs had been sold at swap meets in Illinois, Indiana, and Ohio. In at least one case of monkeypox in this outbreak, an infected prairie dog at an animal clinic transmitted infection to a rabbit, who was the source of primary infection (CDC, 2003a). In this outbreak, 72 cases of monkeypox were reported to the CDC from Illinois, Wisconsin, Indiana, Kansas, Missouri, and Ohio. No specific treatment is known, but supportive and symptomatic care, use of antiviral medications such as cidofovir, and (potentially) vaccinia immune globulin may be useful (Frey & Belshe, 2004). No deaths occurred in this outbreak, and smallpox vaccine was administered both pre-exposure and post-exposure to persons at occupational risk (CDC, 2003b; DiGiulio & Eckburg, 2004b).
...a microbe can [easily] traverse great distances.
This outbreak is an example of how easily a microbe can traverse great distances. It also illustrates a challenge to public health protection, the import of live animals across borders as exotic pets without the necessary oversight (Lashley, 2004). In this outbreak of monkeypox, an embargo on the import, sale, and transport of rodents from Africa and on the sale or movement of prairie dogs was announced on June 11, 2003. However, there is a large illegal trade in animals brought into the United States, and this poses a danger for further instances of transmission of zoonotic diseases (animal diseases that can be transmitted to humans). Another concern is whether or not monkeypox virus has established a reservoir in North America (DiGiulio & Eckburg, 2004a).
...when a clinician observes patients with atypical rashes, with or without encephalitis, monkeypox may need to be considered in the differential diagnosis.
In Africa, the mortality rate for monkeypox virus infection is between 1% and 10%, and can be higher in children or those who are immunosuppressed (CDC, 2003a). The usual mode of transmission is through the bite of or close contact with an infected animal. Acquisition of monkypox in Africa is associated with preparation and eating of infected rodents and monkeys (Fleischauer et al., 2005). Person-to-person transmission has been previously documented by direct contact and respiratory droplet spread, and there is a theoretical risk for airborne transmission (CDC, 2003d). The risk for person-to-person transmission, while considered rare, is of particular concern to health care workers (Fleischauer et al., 2005).
One lesson learned is that when a clinician observes patients with atypical rashes, with or without encephalitis, monkeypox may need to be considered in the differential diagnosis. This is especially true if they have had recent travel to Africa or have exposure to exotic animals or pets (Sejvar et al., 2004). Another lesson is the need for appropriate use of effective infection control. Because severe illness, with no specific treatment, can result from monkeypox virus infection, it is also considered to be a possible agent for use by bioterrorists.
Bovine Spongiform Encephalopathy (BSE)
BSE is a transmissible spongiform encephalopathy (TSE). TSEs are progressively fatal, incurable neurodegenerative diseases that are considered to be prion diseases. Prion proteins that are altered, usually through conformational changes such as misfolding, cause three categories of disease in humans: sporadic, infectious/iatrogenic, and genetic/familial (Glatzel, Stoeck, Seeger, Lührs, & Azguzzi, 2005). Prion diseases include:
- Bovine spongiform encephalopathy (BSE), commonly referred to as "mad cow" disease.
- Kuru, which was spread horizontally among the Fore people of New Guinea who practiced ritualistic cannibalism, often in conjunction with certain death rituals. Kuru has died out in the Fores born since cannibalism has been banned.
- Scrapie, a neurological disease in sheep and goats.
- Creutzfeldt-Jakob disease (CJD) (sporadic, familial or variant), in humans.
- Chronic wasting disease of certain animals such as elk and mink.
- Certain genetically determined or familial disorders (e.g., fatal familial insomnia and Gerstmann-Sträusssler-Scheinker syndrome).
Variant Creutzfeldt-Jakob disease (vCJD) is considered to be causally linked to eating beef products contaminated with the prions that cause BSE (Belay et al., 2005). Classic CJD and vCJD are similar but vCJD occurs in younger persons, particularly under 50 years of age. Patients tend to present with behavioral changes or progressive neuropsychiatric symptoms, such as cerebellar ataxia, cognitive impairment, incontinence, dementia, and progression to mutism. The incubation period is long, usually years. Death is inevitable.
Most publicity and lay public concern about the TSEs has related to potential BSE transmission to humans from eating infected meat or meat products. Another area of concern, especially among health care professionals, is the actual and potential transmission through blood transfusions; transmission via corneal, dura mater, and other transplants; or other iatrogenic means (Lashley, 2002a). Concern has also arisen over potential transmission of prion diseases through inadequately sterilized instruments or devices.
The current BSE epidemic in the United Kingdom emerged in the 1980s, and epidemics have been reported in many other countries. Linkage to vCJD was first noted in a 1996 report (Will et al., 1996). In the United States, no identified cases of BSE occurred in cows until 2003, when it was identified in a dairy cow in Washington that had been imported from Canada. In June, 2005, BSE was confirmed in a 12 year old cow in Texas that was born in the United States (Belay et al., 2005). In late July, 2005, a third cow was detected in the United States (BSE Update, 2005).
The 2003 case of BSE resulted in a number of economic sanctions against U.S. beef. Another result was the implementation of precautions and preventive activities to protect the food supply and enhance surveillance for clinical features of variant Creutzfeldt-Jakob disease (CDC, 2004). As of June 2005, 156 vCJD patients have been reported from the United Kingdom, 13 from France, 3 from Ireland, and one each from Canada, Italy, Japan, Portugal, and the Netherlands (Belay et al., 2005). One vCJD case has been identified in the U.S. This case was in a Florida woman who died in 2004, and who most likely acquired the disease when she lived in Great Britain (Belay et al., 2005).
Severe Acute Respiratory Syndrome (SARS)
Another example of the rapid emergence of a newly recognized human disease agent is the human coronavirus that causes SARS. SARS has been called the first pandemic of the 21st century (Skowronski et al., 2005). In late 2002, reports began to circulate about an "unusual" respiratory disease in southern China, first thought to possibly be an unusual strain of influenza. In February 2003, a physician who was incubating SARS traveled from Guangdong province to Hong Kong. He apparently transmitted SARS to local residents and other travelers, who then returned to their countries of Vietnam, Singapore, Canada, and Taiwan (Breiman et al., 2003). The WHO first reported an outbreak of "acute respiratory syndrome" in China in the February 14, 2003 issue of the Weekly Epidemiological Record, but a period of time passed before international notification occurred (WHO, 2003). The number of reported cases escalated worldwide through May 2003 and then began to decelerate. By mid-July, just under 8, 500 cases had been identified (CDC, 2003c). On July 5, the WHO announced containment of the SARS global outbreak; however, it also warned that SARS was not gone.
Rapid scientific attention resulted in the identification of a "novel" coronavirus as the causative agent (Drosten et al., 2003; Ksiazek, Erdman, & Goldsmith, 2003; Peiris et al., 2003). During the SARS outbreak, various definitions of the disease emerged, and a range of infectivity estimates were made. Isolation was deemed important, and it was noted that there was a very high attack rate among health care workers, as well as clustering of cases in community settings such as apartment buildings in Hong Kong. This demonstrated that SARS was highly contagious through close person-to-person contact. Airborne transmission was postulated as possible; SARS was also rapidly spread through air travel. Containment was difficult and it was uncertain whether a seasonal pattern would develop, much like that of influenza. It was believed that the SARS virus may have originated from wildlife, who are often in crowded markets and may be eaten.
SARS has been called the first pandemic of the 21st century.
Effects of this outbreak included uncertainties and fear that, in some cases, resulted in debates and policies against students returning to their U.S. universities from Asia after spring break, and travel restrictions to Hong Kong, parts of China (such as Beijing), Toronto, Canada, and Taiwan. Restrictions had political and economic consequences. Even Asian merchants in unaffected areas experienced a decrease in business, and in other areas, conventions and similar activities were canceled.
Identification of SARS cases in Singapore in September 2003 led to concerns about a possible resurgence in the upcoming winter. This concern proved valid. In early January 2004, China announced a case of SARS from Guangdong; reports of other cases soon followed (WHO, 2004). In response, Chinese health officials slaughtered 10,000 civet cats and other mammals and started a campaign against rats and cockroaches to prevent spread (Normile, 2004; Watts, 2004). On retrospective study, SARS-related virus antibodies were found in serum samples collected in May 2001, indicating that some persons were exposed prior to the 2003 outbreak (Senior, 2004; Zheng, Guan, & Wong, 2004).
West Nile Virus
West Nile virus is a single-stranded RNA flavivirus (Higgs, Schneider, Vanlandingham, Lingler, & Gould, 2005). The most frequent means of transmission is from the bite of an infected mosquito, especially Culex mosquitoes. Mosquitoes may be involved in a complex cycle when they acquire the virus from viremic wild bird reservoirs or other infected vertebrates, including horses and humans. Transmission may also occur through blood transfusion, tissue and organ transplantation, transplacentally from mother to child, and probably through breastfeeding. West Nile virus infection may also occur through direct inoculation, (e.g., among laboratory workers, or those who handle infected animals) (CDC, 2002). A disturbing report also indicates that nonviremic transmission with horizontal transfer of the virus can occur (Higgs, Schneider, Vanlandingham, Lingler, & Gould, 2005). Clinically, there are three basic outcomes following infection with West Nile virus, as follows:
- No discernable symptoms. This outcome occurs in about 80% of those infected;
- Development of West Nile fever, a mild illness with flu-like symptoms that is self-limited in immunocompetent individuals. This occurs in approximately 20% of those infected; and
- Development of central nervous system infection, usually manifested as encephalitis or meningitis. Signs and symptoms include: fever, headache, gastrointestinal symptoms, stiff neck, alterations in consciousness and mental status such as lethargy, seizures, weakness, focal neurological deficits, movement disorders, and others. This outcome occurs in less than 1% of those infected, most frequently in those who are over the age of 50 years (Dean & Palermo, 2005; Granwehr et al., 2004; Watson, Bartt, Houff, Leurgans, & Schneck, 2005).
West Nile virus was first identified in 1937 from a person in the West Nile district of Uganda. Outbreaks were infrequent until 1996 when more significant outbreaks, with hundreds of persons manifesting neurological signs and symptoms, occurred in countries such as Romania, Russia, and Israel (Lashley, 2002b; Smithburn, Hughes, Burke, & Paul, 1940).
The most frequent means of transmission [of West Nile virus] is from the bite of an infected mosquito, especially Culex mosquitoes...health care providers should be able to educate consumers about protective measures.
North America has only really been aware of West Nile virus since 1999, when a cluster of unusual cases of encephalitis in New York City heralded the arrival of West Nile virus in North America (CDC, 1999a; Lashley, 2002b). That year, 62 human cases were identified (CDC, 1999b). This introduction has been called the "perfect microbial storm" because certain factors were present at that point in time (Glaser, 2004, p.557). These factors included large, non-immune animal and human populations; multiple vectors; and a favorable environment for transmission and dissemination. West Nile virus spread quickly across the continent, and within 5 years established itself as endemic in the United States (Glaser, 2004). As of June 21, 2005, the number of human cases of West Nile Virus reported to the CDC was 2,539, with at least one case reported in each state. This is likely an under report, since West Nile virus infection is not a nationally notifiable disease (CDC, 2005b).
No specific treatment for West Nile virus is available. Prevention methods center around minimizing the opportunity for mosquito bites through the use of environmental controls, personal protection, surveillance, and reporting activities. "Emerging Infectious Diseases: Trends and Issues," by Lashley and Durham (2002), provides additional details about preventive methods. Personal protective behaviors associated with decreased risk of mosquito bites include wearing long sleeves and long pants, using insect repellant, avoiding exposure to mosquitoes, and avoiding outside leisure activities at dawn and dusk (Loeb et al., 2005). Health care providers should be able to educate consumers about protective measures. They should also be alert to the possibility of an outbreak of West Nile virus anywhere across North America, in eastern Europe, Israel, Africa, and elsewhere.
To some extent, the influenza virus has excited the imagination to a lesser degree than many other emerging viral diseases.
On the possibility of an avian influenza pandemic arising, Michael Osterholm, director of the Center for Infectious Disease Research at the University of Minnesota, has said "We’re screwed" if it hits soon (Querna, 2005, para. 3). To some extent, the influenza virus has excited the imagination to a lesser degree than many other emerging viral diseases. However, it indeed fits into this category because of its ability to genetically change often and rapidly. This ability to mutate is one of the reasons that each year there are seasonal epidemics, and the necessity to produce vaccines targeted for the appropriate strain(s) in the upcoming influenza season.
Influenza virus types A and B infect humans and can cause widespread outbreaks. Type A tends to be the most severe. Influenza virus subtypes are referred to by their hemagglutinen (H) and neuraminidase subtypes (N) which are surface glycoproteins of the virus, such as the avian influenza virus subtype H5N1 (Moorman, 2003). The influenza virus is considered to have the potential for use as an agent for bioterrorism, most probably by alteration to a mutated form with greater infectivity, greater virulence, more efficient human-to-human transmission, and antiviral resistance.
There have been several great influenza pandemics, notably in the years:
- 1918-19: "Spanish flu" (caused 20 to 40 million deaths worldwide; a large proportion of deaths occurred in healthy adults 15 to 35 years of age)
- 1957: "Asian flu"
- 1968: "Hong Kong flu"
- 1977: "Russian flu"
In the United States each year, approximately 100,000 people are hospitalized with influenza, and about 36,000 die. Thomas Abraham warned of "a biological tsunami" brewing in regard to avian influenza (Abraham, 2005). There is fear that avian influenza could become pandemic in the very near future.
Avian influenza viruses are those carried by birds (usually wild birds)who then shed virus in saliva, nasal secretions, and feces. Birds or fowl become infected when they come into contact with secretions or excretions from infected birds, most often through fecal-oral transmission. Transmission also occurs through contact with surfaces or materials such as feed, water, cages, or dirt that are contaminated with the virus. Contaminated cages, for example, can carry the virus from one place to another.
Quarantine and depopulation [of birds] are common controls for outbreaks of avian influenza.
The first documented direct transmission of an avian influenza virus (H5N1) to humans occurred in 1997 in Hong Kong. Limited human-to-human transmission was also thought to occur. Severe respiratory disease occurred in 18 healthy young adults and children and 6 died. Live poultry markets were the source of the virus strain in this outbreak. Many Asian people prefer to buy fresh foods at so-called "wet-markets," which are increasing in number. In both influenza and SARS, wet markets have been implicated as sources of virus transmission. This illustrates a cultural influence on emergence of infectious diseases.
Quarantine and depopulation (or culling of birds) are common controls for outbreaks of avian influenza. For example, the 1997 outbreak was controlled by slaughter of the poultry population. More than 1.2 million chickens and 0.3 million other poultry were killed and imports of chickens from Hong Kong and China were banned by other countries (Bridges et al., 2002).
Of concern is the possible mutation of the avian influenza virus to allow sustained person-to-person transmission.
In 1999, avian influenza viruses H9N2 were isolated in Hong Kong from children with mild influenza. One died. In 2003, the avian influenza virus strain H7N7 occurred in poultry farms in the Netherlands, spreading to Germany and Belgium. Infection, mainly conjunctivitis, occurred in humans, with 1 death. The 2003 outbreak was also controlled by the destruction of over 30 million domestic poultry. In British Columbia, Canada, an outbreak of avian influenza H7N3 occurred in poultry; human cases presented with conjunctivitis and mild flu-like symptoms (Monto, 2005; Tweed et al., 2004).
In 2003, the avian influenza virus strain, H5N1, emerged in 2 family members in Hong Kong after traveling in China. Also in 2003, an outbreak of avian influenza virus, H5N1, occurred in South Korea, and in 2004, it emerged in Vietnam and Thailand. Many countries banned the import of poultry products from the Asian countries affected. Other countries in which poultry were infected included Canada, Japan, Laos, North Korea, China, Cambodia, Malaysia, Rumania, and Indonesia. Human cases presented with severe respiratory infection and out of 108 known and confirmed cases recognized from January 2004 to June 28, 2005, 54 died. Probable human-to-human transmission was recognized (CDC, 2005c; Ungchusak et al., 2005). In rural Asia, many households maintain poultry for income and food, and increase the opportunity for human exposure (Stöhr, 2005).
Of concern is the possible mutation of the avian influenza virus to allow sustained person-to-person transmission. Noting the spread of avian influenza in 2004 to 2005, various conferences have addressed plans for surveillance and control, vaccine production, and treatment involving global cooperation among agencies such as the WHO, the Food and Agriculture Organization, and the World Organization for Animal Health (Avian influenza - Eastern Asia, 2005; Knobler, Mack, Mahmoud, & Lemon, 2005; WHO, 2005a).
EIDs and the Future
The emergence and re-emergence of infectious diseases involves many interrelated factors.
The emergence and re-emergence of infectious diseases involves many interrelated factors. Global interconnectedness continues to increase with international travel and trade; economic, political, and cultural interactions; and human-to-human and animal-to-human interactions. These interactions include the accidental and deliberate sharing of microbial agents and antimicrobial resistance and allow the emergence of new and unrecognized microbial disease agents. As the 21st century begins, already new agents have been identified, and new outbreaks have occurred. Solutions to limiting the spread of EIDs will require cooperative efforts among many disciplines and entities worldwide.
Most public health experts do not ask if one or more large scale pandemics will occur. They ask "When?"
Most public health experts do not ask if one or more large scale pandemics will occur. They ask "When?" Avian influenza unfortunately holds the potential to be the disease that will illustrate that point. While there have been steps taken for effective prevention and strategies developed for dealing with a pandemic, globally these preparations are far from adequate. Many ethical and social issues have not been addressed in depth.
Long-term strategies are discussed in detail by the IOM report (Smolinski, Burger, & Lederberg, 2003) and others (Lashley, 2004). Among the keys to success will be adequate financial resources, knowledge sharing, rapid communication, and cooperation among health care professionals and experts in human behavior, politics, economics and other disciplines. For nurses, this must include the awareness of unusual symptoms or clusters of disease; provision of appropriate education; and acquisition of equipment and supplies needed to maintain infection control, and the authority to implement these, to assure the best possible patient and family care in the event of infectious disease.
Felissa R. Lashley, RN, PhD, ACRN, FAAN, FACMG
Felissa R. Lashley (formerly Cohen) is professor and Dean of the College of Nursing at Rutgers, The State University of New Jersey, and interim director of the Nursing Center for Bioterrorism and Emerging Infectious Diseases Preparedness. Immediately prior to this appointment she was professor and Dean of the School of Nursing, Southern Illinois University Edwardsville from 1995-2002. She has also held positions as a clinical professor of pediatrics at the SIU School of Medicine, professor and Head of the Department of Medical-Surgical Nursing at the University of Illinois at Chicago College of Nursing, Clinical Chief for Medical-Surgical Nursing at the University of Illinois Hospital and Clinics, and director of the Center for Narcolepsy. She received a BS, RN from Adelphi College, an MA in medical surgical nursing/higher education from New York University and a PhD in human genetics from Illinois State University.
Dr. Lashley is the first nurse certified as a PhD medical geneticist by the American Board of Medical Genetics and is a founding fellow of the American College of Medical Genetics. She began providing clinical genetic services and genetic counseling in 1973. She has a certificate in medical genetics from Jackson Laboratories. She is a fellow of the American Academy of Nursing.
Dr. Lashley is author of more than 300 publications, and presents nationally and internationally on a variety of topics. The first and second editions of her book, Clinical Genetics in Nursing Practice, received Book of the Year Awards from the American Journal of Nursing (AJN). Three other books have been awarded AJN Book of the Year: The Person with AIDS: Nursing Perspectives (Durham & Cohen, Eds), Women, Children and HIV/AIDS (Cohen & Durham), and Emerging Infectious Diseases: Trends and Issues (Lashley & Durham) (also a Choice awardee). Tuberculosis: A Sourcebook for Nursing Practice (Cohen & Durham) won a Book of the Year Award from Nurse Practitioner.
Dr. Lashley has received several million dollars in external research funding. She has served as a grant reviewer, on research advisory groups at National Institutes of Health (NIH), and was a member of the charter AIDS Research Review Committee, National Institute of Allergy and Infectious Disease, NIH. Dr. Lashley has received research awards from the Association of Nurses in AIDS Care and the Illinois Nurses Association. She has received an Exxon Education Foundation Innovation Award, the SAGE award from the Illinois Leadership Institute for mentoring nurse leaders, and the distinguished alumni award from Illinois State University. She is a distinguished lecturer for Sigma Theta Tau International, and was an associate editor of the journal, IMAGE: The Journal of Nursing Scholarship. She is a member of the editorial boards of AIDS Education and Prevention, Nursing and Health Sciences, and Biological Research In Nursing. She is a member of the Board of Directors of Robert Wood Johnson University Hospital in New Brunswick, NJ, and of the statewide NJ MEDPREP committee. She has been selected as a "woman of excellence" by the New Jersey Women In AIDS Network.
Abraham, T. (2005). Preparing for a new global threat: Part II. YaleGlobal, 28. Retrieved July 30, 2005 from: http://yaleglobal.yale.edu/display.article?id=5191.
Arthur, R.R. (2002). Ebola in Africa—discoveries in the past decade. Euro Surveillance, 7, 33-36.
Avian influenza - Eastern Asia (64): FAO/OIE/WHO. (2005, July 6). ProMed 2005 (No. 285), unpaginated.
Belay, E.D., Sejvar, J.J., Shieh, W-J, Wiersma, S.T., Zou, W-Q, Gambetti, P., et al. (2005 Sept.). Variant Cretzfeldt-Jakob disease death, United States. Emerging Infectious Diseases, 11, Retrieved July 30, 2005 from: www.cdc.gov/ncidod/EID/vol11no09/05-0371.htm .
Breiman, R.F., Evans, M.R., Preiser, W., Maguire, J., Schnur, A., Li, A., et al. (2003). Role of China in the quest to define and control severe acute respiratory syndrome. Emerging Infectious Diseases, 9, 1037-1041. Retrieved December 15, 2005 from: www.cdc.gov/ncidod/EID/vol9no9/03-0390.htm.
Bridges, C.B., Lim, W., Hu-Primmer, J., Sims, L., Fukuda, K., Mak, K.H., et al. (2002). Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. Journal of Infectious Diseases, 185, 1005-1010.
BSE update 2005 (03). (2005). ProMed Digest 2005 No. 325, unpaginated
Centers for Disease Control and Prevention. (1999a). Outbreak of West Nile-like viral encephalitis–-New York, 1999. Morbidity and Mortality Weekly Report, 48, 845-849.
Centers for Disease Control and Prevention. (1999b). Update:West Nile virus encephalitis–-New York, 1999. Morbidity and Mortality Weekly Report, 48, 944-955.
Centers for Disease Control and Prevention. (2001). Outbreak of Ebola hemorrhagic fever–Uganda, August 2000-January 2001. Morbidity and Mortality Weekly Report, 50, 73-77.
Centers for Disease Control and Prevention. (2002). Possible West Nile virus transmission to an infant through breast-feeding—Michigan 2002. Morbidity and Mortality Weekly Report, 51, 877-878.
Centers for Disease Control and Prevention. (2003a). Multistate outbreak of monkeypox. Morbidity and Mortality Weekly Report, 52, 537-540.
Centers for Disease Control and Prevention. (2003b). Update: Multistate outbreak of monkeypox—Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. Morbidity and Mortality Weekly Report, 52, 642-646.
Centers for Disease Control and Prevention. (2003c). Update: severe acute respiratory syndrome--worldwide and United States, 2003. Morbidity and Mortality Weekly Report, 52, 664-665.
Centers for Disease Control and Prevention. (2003d). Updated interim infection control and exposure management guidance in the health-care and community setting for patients with possible monkeypox virus infection. Retrieved July 30, 2005 from: www.cdc.gov/ncidod/monkeypox/infectioncontrol.htm
Centers for Disease Control and Prevention. (2004). Bovine spongiform encephalopathy in a dairy cow--Washington State, 2003. Morbidity and Mortality Weekly Report 52, 1280-1285.
Centers for Disease Control and Prevention. (2005a). Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S. hospitals. Retrieved July 30, 2005 from: www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html
Centers for Disease Control and Prevention. (2005b). 2005 West Nile virus activity in the United States. Retrieved July 30, 2005 from: www.cdc.gov/ncidod/dvbid/westnile/surv%26controlCaseCount05_detailed.htm
Centers for Disease Control and Prevention. (2005c). Recent avian influenza outbreaks in Asia and Europe. Retrieved July 6, 2005 from: www.cdc.gov/flu/avian/outbreaks/asia.htm
Dean, J.L., & Palermo, B.J. (2005). West Nile virus encephalitis. Current Infectious Disease Reports, 7, 292-296.
DiGiulio, D.B., & Eckburg, P.B. (2004a). Human monkeypox: an emerging zoonosis. Lancet, 4, 15-25.
DiGiulio, D.B., & Eckburg, P.B. (2004b). Monkeypox in the western hemisphere. New England Journal of Medicine, 350, 1790-1791.
Drosten, C., Gunther, S., Preiser W., van der Werf, S., Brodt, H.R., Becker, S., et al. (2003). Identification of a novel coronavirus associated with severe acute respiratory syndrome. New England Journal of Medicine, 348, 1967-1976.
Feldman, H., & Kiley, M. P. (2000). Classification, structure and replication of filoviruses.Current Topics in Microbiology and Immunology, 235, 1-19.
Fleischauer, A.T., Kile, J.C., Davidson, M., Fischer, M., Karem, K.L., Teclaw, R., et al. (2005). Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clinical Infectious Diseases, 40, 689-694.
Frey, S.E., & Belshe, R.B. (2004). Poxvirus zoonoses–putting pocks into context. New England Journal of Medicine, 350, 324-327.
Georges, A.J., Leroy, E.M., Renaut, A.A., Benissan, C.T., Nabias, R.J., Ngoc, M.T., et al. (1999). Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: Epidemiologic and health control issues. Journal of Infectious Diseases, 179 (Suppl. 1), S65-S75.
Glaser, A. (2004). West Nile virus and North America: An unfolding story. Scientific and Technical Review, 23, 557-568.
Glatzel, M., Stoeck, K., Seeger, H., Lührs, T., & Azguzzi, A. (2005). Human prion diseases: Molecular and clinical aspects. Archives of neurology, 62(4), 545-552.
Granwehr, B.P., Lillibridges, K.M., Higgs, S., Mason, P.W., Aronson, J.F., Campbell, G.A., et al. (2004). West Nile virus: Where are we now? Lancet, Infectious Diseases, 4, 547-546.
Higgs, S., Schneider, B.S., Vanlandingham, D.L., Klingler, K.A., & Gould, E.A. (2005). Nonviremic transmission of West Nile virus. Proceedings of the National Academy of Sciences USA, 102, 8871-8874.
Irani, D.N., & Johnson, J.T. (2003). Diagnosis and prevention of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. Annual Review of Medicine, 54, 305-319.
Johnson, E., Jaax, N., White, J., & Jahrling, P. (1995). Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. International Journal of Experimental Pathology, 76, 227-236.
Knobler, S.L., Mack, A., Mahmoud, A., & Lemon, S. M. (Eds.). (2005). The threat of pandemic influenza: Are we ready? Washington, DC: National Academies Press.
Ksiazek, T.G., Erdman, D., & Goldsmith, C.S. (2003). A novel coronavirus associated with severe acute respiratory syndrome. New England Journal of Medicine, 348, 1953-1966.
Lashley, F.R.. (2002a). Categories and highlights of significant current emerging infectious diseases. In: F.L. Lashley & J.D. Durham, (Eds). Emerging Infectious Diseases: Trends and Issues. (pp. 43-71). New York: Springer Publishing Company.
Lashley, F.R.. (2002b). West Nile virus. In: F.L. Lashley & J.D. Durham, (Eds). Emerging Infectious Diseases: Trends and Issues. (pp. 255-262). New York: Springer Publishing Company.
Lashley, F.R. (2003). Factors contributing to the occurrence of emerging infectious diseases. Biological Research for Nursing, 4, 258-267.
Lashley, F.R. (2004). Emerging infectious diseases: Vulnerabilities, contributing factors and approaches. Expert Review of Anti-infective Therapy, 2, 299-316.
Lashley F.R., & Durham, J.D. (eds). (2002). Emerging infectious diseases: Trends and issues. New York: Springer Publishing Company.
Lederberg, J., Shope, R.E., & Oaks, Jr., S.C. (1992). Emerging infections:Microbial threats to health in the United States. Washington, DC: Institute of Medicine, National Academies Press.
Liu, J. (2003). SARS, wildlife and human health. Science, 302, 53.
Loeb, M., Elliott, S.J., Gibson, B., Fearon, M., Nosal, R., Drebot, M., et al. (2005). Protective behavior and West Nile virus risk. Emerging Infectious Diseases, 11. Retrieved July 30, 2005 from: www.cdc.gov/ncidod/EID/vol11no09/04-1184.htm.
Monto, A.S. (2005). The threat of an avian influenza pandemic. New England Journal of Medicine, 352, 323-325.
Moorman, J.P. (2003). Viral characteristics of influenza. Southern Medical Journal, 96, 758-761.
Normile, D. (2004). Viral DNA match spurs China’s civet roundup. Science, 303, 292.
Peiris, J.S.M., Lai, S.T., Poon, L.L.M., Guan, Y., Yam, L. Y., Lin, W., et al. (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 361,1319-1325.
Peters, C.J., & LeDuc. J.W. (1999). An introduction to Ebola: The virus and the disease. Journal of Infectious Diseases, 179 (Suppl. 1), ix-xvi.
Preston, R. (1994). The hot zone: A terrifying true story. New York, NY: Random House.
Pourrut, X., Kumulungui, B., Wittmann, T. Moussavou, G., Délicat, A., Yaba, P., et al. (2005). The natural history of Ebola virus in Africa. Microbes and Infection, 7,1005-1014.
Querna, B. (2005, June 16). Avian flu: ‘We’re screwed’ if it hits soon. USNews.com. Retrieved July 30, 2005 from: www.usnews.com/usnews/health/articles/050616/16avian.htm.
Reed, K.D., Melski, J.W., Graham, M.B., Regnery, R.L., Sotir, M.J., Wgne, M.V., et. al. (2004). The detection of monkeypox in humans in the Western hemisphere. New England Journal of Medicine, 350, 342-350.
Sejvar, J.J., Chowdary, Y., Schomogyi, M., Stevens, J., Patel, J., Karem, K., et al. (2004). Human monkeypox infection: A family cluster in the midwestern United States. Journal of Infectious Diseases, 190, 1833-1840.
Senior K. (2003). Recent Singapore SARS case a laboratory accident. Lancet Infectious Diseases 3, 679.
Smith, D.H., Johnson, B.K., Isaacson, M., Swanepoel, R., Johnson, K.M., Killey, M., et al. (1982). Marburg-virus disease in Kenya. Lancet, 1, 816-820.
Smithburn, K.C., Hughes, T.P., Burke, A.W., & Paul, J.H. (1940). A neurotropic virus isolated from the blood of a native of Uganda. American Journal of Tropical Medicine, 20, 471-492.
Skowronski, D.M., Astell, C., Brunham, R.C., Low, D.E., Petric, M., Roper, R.L., et al. (2005). Annual Review of Medicine, 56, 357-381.
Smolinski, M. S., Hamburg, M.A., & Lederberg, J. (eds). Microbial threats to health: Emergence, detection, and response. Washington, DC: Institute of Medicine, National Academies Press.
Stöhr, K. (2005). Avian influenza and pandemics—research needs and opportunities. New England Journal of Medicine, 352, 405-407.
Tweed, S.A., Skowroski, D.M., David, S.T., Larder, A., Petric, M., Lees, W., et al. (2004). Human illness from avian influenza H7N3, British Columbia. Emerging Infectious Diseases, 10, 2196-2199.
Ungchusak, K., Auewarakul, P., Dowell, S.F., Kitphati, R., Auwanit, W., Puthavathana, P., et al. (2005). Probable person-to-person transmission of avian influenza A (H5N1). New England Journal of Medicine, 352, 333-340.
Warner Brothers Pictures. (1995). Outbreak [videorecording]. Burbank, CA: Warner Home Video.
Watson, N.K., Bartt, R.E., Houff, S.A., Leurgans, S.E., & Schneck, M.J. (2005). Focal neurological deficits and West Nile virus infection. Clinical Infectious Diseases, 40, e59-e62.
Watts J. (2004). China culls wild animals to prevent new SARS threat. Lancet, 363, 134.
We have been warned. (2003). Nature, 424, 6945.
Wenzel, R.P., & Edmond, M.B. (2003). Managing SARS amidst uncertainty. New England Journal of Medicine, 348, 1947-1948.
Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., Alperovitch. A., et al. (1996). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 347, 921-925.
World Health Organization. (2001). Outbreak news. Ebola, Uganda (update). Weekly Epidemiologic Record, 76, 1.
World Health Organization. (2003). Acute respiratory syndrome, China. Weekly Epidemiology Review, 78 , 41-48.
World Health Organization. (2004). Announcement of suspected severe acute respiratory syndrome (SARS) case, southern China (update). Weekly Epidemiological Record, 79, 14-16.
World Health Organization. (2005a). Avian influenza: Assessing the pandemic threat. Geneva, Switzerland: World Health Organization.
World Health Organization. (2005b). Communicable Disease Surveillance & Response, August 24. Geneva, Switzerland: World Health Organization. Retrieved December 12, 2005 from: www.who.int/csr/don/2005__08_24/en/index.html.
World Health Organization. (2005c). Communicable Disease Surveillance & Response, November 07. Geneva, Switzerland: World Health Organization. Retrieved December 12, 2005 from: www.who.int/csr/don/2005__11_07/en/index.html.
Zheng, B.J., Guan, Y., & Wong, K. H. (2004). SARS-related virus predating SARS outbreak, Hong Kong. Emerging Infectious Diseases, 10, 176-178.
© 2006 Online Journal of Issues in Nursing
Article published January 31, 2006
- The Impact of Tuberculosis on Zambia and the Zambian Nursing Workforce
Dorothy Chanda, MPH, BSCN, PHN, IPN, SCM, SRN; Davina J. Gosnell, RN, PhD, FAAN (January 31, 2006)
- Motivating HIV Positive Women to Adhere to Antiretroviral Therapy and Risk Reduction Behavior: The KHARMA Project
Marcia McDonnell Holstad, DSN, RN, C, FNP; Colleen DiIorio, PhD, RN, FAAN; Mabel K. M. Magowe, MSN, RN (January 31, 2006)
- The 2003 SARS Outbreak: Global Challenges and Innovative Infection Control Measures
Cathryn Murphy RN, MPH, CIC, PhD (January 31, 2006)
- Early Detection and Surveillance for Biopreparedness and Emerging Infectious Diseases
Tener Goodwin Veenema PhD, MPH, MS, CPNP; Joanna Tõke, MPH (January 31, 2006)
- Using Theory to Interpret Beliefs in Migrants Diagnosed with Latent TB
Lora L. Wyss, PhD, RN, CNS;M. Kay Alderman, EdD (November 16, 2006)
- Influenza Vaccination in Healthcare Workers: Should it be Mandatory?
Paula L. Sullivan, DHSc, MSN, APRN (November 2, 2009)